Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 ...
Affimed Receives FDA Fast Track Designation for AFM13 in Combination ...
In this photo illustration, the Affimed logo is displayed on a ...
Affimed NV | Biotechnology | The Pharmaletter | The Pharmaletter
Affimed Announces New Innate Cell Engager AFM28 Targeting
AFM13 / Affimed
Affimed on LinkedIn: #afm13 #afm24 #nkcells #clinicalresearch
Affimed Corporate Deck April 2024 | PDF | Epidermal Growth Factor ...
Affimed on LinkedIn: #afm13 #icymi
Affimed Gains FDA Nod for Lymphoma IND Combination - TipRanks.com
Affimed - AFM13 - Science and Technology - Innate Cell ...
#afm13 #afm28 #afm24 #affimedproud #whywefightcancer | Affimed
Affimed NV (NASDAQ:AFMD) Administers AFM13 Dose To The First Phase 1 ...
Affimed präsentiert neue AFM13-Daten | GoingPublic.de
Affimed is seeking funds - European Biotechnology Magazine
Affimed (AFMD) Shifts Attention To Risky Combination Therapy | Seeking ...
Affimed Therapeutics | EquityNet
Effective Q1 2024 Affimed NV Presentation Design for Cancer Therapies ...
Affimed natural killer cell therapy boasts encouraging results
Affimed N.V. Completes Enrollment in NSCLC Cohort and Prepares for Data ...
Affimed Reports First Quarter 2024 Updates - OncoDaily
#afmd #immunooncology #innateimmunity #whtwefightcancer | Affimed
Affimed on LinkedIn: #afmd #afm24 #whywefightcancer
Affimed on LinkedIn: #asco23 #afmd #afm24 #immunooncology #innateimmunity
#immunotherapy #immunooncology #nkcelltherapy #cancer | Affimed
Affimed Presentation-Mar2020 Final-1 PDF | PDF | Natural Killer Cell ...
#afm28 #innateimmunity #immunooncology #whywefightcancer | Affimed
AFM11 / Affimed
Affimed on LinkedIn: #lymphoma #whywefightcancer #affimedproud #afm13 # ...
#afmd #immunooncology #innateimmunity | Affimed
FDA grants RMAT to Affimed and Artiva’s lymphoma therapy
Affimed begins subject dosing in AML therapy trial
Affimed and Roivant Sciences Announce Licensing and
Looking to make a difference for cancer patients? Join the Affimed team ...
Affimed Announces Encouraging Phase 1 Results for AFM28 in Treating R/R AML
Video: Affimed Shares Surge 18%: Elevation Oncology's Big Move!
Affimed logo in transparent PNG and vectorized SVG formats
Hat sich bei Affimed das Warten gelohnt?
Affimed on LinkedIn: #afmd #afm24 #immunooncology #innateimmunity # ...
#womenataffimed #affimedproud #teamgeist | Affimed
Affimed Therapeutics 2018 Q3 - Results - Earnings Call Slides (NASDAQ ...
Streamlined Mandatory Training For Affimed With Learn365
Affimed on LinkedIn: #afmd #innateimmunity #whywefightcancer
Affimed (AFMD) Stock Forecast and Price Target 2026
Affimed NV - AnnualReports.com
Affimed and NKGen Biotech Announce Initiation of Patient
Affimed on LinkedIn: #aacr22 #afm13
Affimed halts trial after patient death and SAEs - European ...
Affimed N.V. (AFMD) BCG Matrix Analysis – DCFmodeling.com
Cantor starts Affimed at OW; PT $12 - BioTuesdays
NK细胞疗法：百家争鸣，突破不断 11月22日，德国临床阶段肿瘤免疫学公司 Affimed 公布了MD Anderson癌症中心研究者发起的 ...
Roche and Affimed in US$5bn cancer deal - European Biotechnology Magazine
Affimed on LinkedIn: #AFM24
Indian Pharma Post on LinkedIn: FDA RMAT status for Affimed and Artiva ...
Affimed 100% ORR的NK疗法进入2期临床，开启肿瘤免疫治疗新篇章 2023年5月25日/医麦客新闻 eMedClub News ...
Affimed (AFMD) analysis deep-dive : Biotechplays
客观缓解率达32.4%，Affimed公布自研药物AFM13|AFM13|细胞淋巴瘤|NK细胞|CD30|PTCL|药物|-健康界
优质的NK细胞是NK细胞疗法的基础，Affimed就此与Artiva展开合作-干细胞&免疫细胞&外泌体&再生医学领域垂直媒体细胞世界
ACTUALIZING THE UNTAPPED POTENTIAL OF THE INNATE IMMUNE SYSTEM ...
Affimed’s AFM13 + AlloNK Receives the US FDA’s Fast Track Designation ...
Slide 1
志同道合NK：AFM13+Pembrolizumab/AFM13+AB101 - 知乎
7 Redirecting and activating immune cells Tetravalent, bispecific ...
癌症疫苗迎来新纪元？KRAS抑制剂再添生力军... | AACR
Redirecting innate cells to kill cancer
TiPLab - 致力于开发创新免疫疗法的Affimed
NK疗法100%ORR缔造者Affimed：商业版图与最新进展梳理 2022年11月18日/医麦客新闻 eMedClub News/--近日 ...
13 Treatment with AFM13 Innate Cell Engagers in Hematologic Tumors ...
Transactions – Laidlaw & Company
Affimed双抗acimtamig与“现货型”NK细胞组合疗法临床结果优秀，针对霍奇金淋巴瘤
| Affimed: Ground-Breaking Advancement in Cancer Treatment-2020
Affimed’s Innate Cell Engager (ICE®) acimtamig combined with Artiva ...
Affimed, Top Immunotherapy Solution Company in Europe-2020
Actualizing the Untapped Potential of the Innate Immune System - June ...
#ash2024 #afmd #afm13 #acimtamig #afm28 #innateimmunity # ...
Affimed: Developing First - In - Class Immune Cell Engagers for ...
AffaMed Therapeutics 与 SIFI 宣布成立合资公司-公司新闻-AffaMed蔼睦医疗
PPF Group | Affimed’s NK cell engager impresses on response rates
2 imágenes, fotos de stock, objetos en 3D y vectores sobre Affimations ...
Actualizing the Untapped Potential of the Innate Immune System ...
Company Listings
德国癌症免疫疗法公司：Affimed N.V.(AFMD) | 美股之家 - 港股美股开户投资百科全书
